[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370780-105":59,"doc-detail-370780-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","evaluation-of-bi-rads-3-ultrasound-findings-the-frequency-and-incidence-of-malignant-lesions-and-tumor-size","Evaluation of BI-RADS 3 Ultrasound Findings - the Frequency and Incidence of Malignant Lesions, and Tumor Size","","Objective of the study is to quantify the frequency of BI-RADS category 3 findings on breast ultrasound relative to the total patient cohort, determine how often malignant lesions are present, and measure the average tumor size at detection. A cross-sectional analysis included 335 women aged 40–75 who met BI-RADS 3 criteria at a Tuzla Breast Center between March 2017 and November 2020. Across 13,760 examinations, BI-RADS 3 accounted for 27%, with recommended short-term follow-up in 9.02%, malignancy in 1.49% (average size 13.6 mm), and no significant difference between pre- and postmenopausal groups; careful monitoring is emphasized.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/evaluation-of-bi-rads-3-ultrasound-findings-the-frequency-and-incidence-of-malignant-lesions-and-tumor-size/370780/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/evaluation-of-bi-rads-3-ultrasound-findings-the-frequency-and-incidence-of-malignant-lesions-and-tumor-size/370780.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does BI-RADS category 3 indicate in breast ultrasound?","Question",{"text":112,"@type":113},"BI-RADS category 3 implies a greater than 0% but ≤ 2% probability of malignancy, characteristic of a likely benign finding that warrants short-term follow-up.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many ultrasound examinations were analyzed, and what proportion were BI-RADS 3?",{"text":117,"@type":113},"A total of 13,760 ultrasound examinations were performed, and BI-RADS category 3 findings accounted for 27% of all examinations (N=3,715).",{"name":119,"@type":110,"acceptedAnswer":120},"What was the malignancy rate and average tumor size among BI-RADS 3 follow-ups?",{"text":121,"@type":113},"Among cases undergoing recommended short-term follow-up, malignancy was identified in 1.49% (N=5), with an average tumor size of 13.6 mm at detection.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370780,1790676789,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Clinical Medicine    \nOriginal Article  \nActa Medica Academica 2025;54(1):1-6 DOI: 10.5644/ama2006-124 .467  \nEvaluation of BI-RADS 3 Ultrasound Findings: the Frequency and Incidence of Malignant Lesions, and Tumor Size  \nHanifa Fejzić, Svjetlana Mujagić, Belkisa Izić  \nDepartment of Radiology and Nuclear Medicine, University Clinical Center, Tuzla, Bosnia and Herzegovina [Correspondence:](Correspondence: fejzic.hanifa@gmail.com)[ fejzic.hanifa@gmail.com](Correspondence: fejzic.hanifa@gmail.com); Tel.: + 387 61 725057  \nReceived: 16 May 2024; Accepted: 25 December 2024  \nAbstract  \nObjective. The aim of the research was to determine the frequency ofBI-RADS category 3 findings in ultrasound examinationsin relation to the total number of patients, the frequency of malignant lesions, and their average size at the time of detection in BI-RADS 3 ultrasound findings. Patients and Methods. A cross-sectional study was performed on 335 patients (aged 40-75 years) classified in BI-RADS category 3, at the Tuzla Breast Center, University Clinical Center, in the period from March 2017 to November 2020. A total of 13,760 ultrasound examinations were performed, using a Toshiba Xario 100 ultrasound machine with a 12 MHz linear probe. Patients were divided into premenopausal and postmenopausal groups, excluding patients with symptoms and those with previous breast cancer surgery. The images were stored using the Institution’s Pictures Activation and Communication System. Results. BI-RADS category 3 findings accounted for 27% of all ultrasound examinations (N=3.715) . Of these, 9.02%(N=335) underwent recommended short-term follow-up. Malignancy was identified in 1.49% of these cases (N=5), with an average tumor size of 13.6 mm at detection. The malignancy rate did not differ significantly between premenopausal and postmenopausal patients (P=0.412). The overall diagnostic yield for malignancy in BI-RADS 3 findings was low, but clinically significant. Conclusion. While the malignancy rate for BI-RADS category 3 findings is low (1.49%), careful monitoring and adherence to follow-up guideline are essential to balance early detection with avoidance of unnecessary biopsies and associated costs.  \nKeyWords: BI-RADS Category 3 􀂃 Ultrasound 􀂃 Tumor Size 􀂃 Breast Cancer 􀂃 Follow-up.  \n\n| Introduction\u003Cbr>The role of breast ultrasound has rapidly expanded from simply characterizing the internal contents of the mass to differentiating between benign and malignant breast masses, and as an adjunctiveto mammography. It has even been proposed as a screening modality in young women or women with dense breasts (1-4) . A BI-RADS category 3 finding should imply a greater than 0% but ≤ 2% probability of malignancy, which is characteristic of a benign finding.\u003Cbr>According to the fifth edition of BI-RADS, ultrasound findings classified as category 3 include complicated cysts; microlobulated or oval areas composed of accumulated microcysts; hypoechoic, well-dellineated, oval horizontaly oriented | areas without posterior acoustic features or with minimal posterior echo enhancment; hyperechoic areas with a central hypo-to anechoic component and surrounding edema consistent with fat necrosis, though not histologically confirmed; refractive shadowing without an associated lesion; and architectural distortion related to postoperative scars.\u003Cbr>Despite the promotion of the BI-RADS lexicon, the main limitations in ultrasound practice are the dependence on operator experience (5) . Bowles et al. (6) showed that increased density of breast shadowing and symptomatic patients were more often receive recommendations for shortterm follow-up, i.e. biopsy or additional imaging. A likely benign finding is not expected to change\u003Cbr>1 |\n| --- | --- |\n\nCopyright © 2025 Fejzić et al. This article is available under a Creative Commons License (Attribution 4.0 International, as described at [https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)).  \nAc","cbCaiafdZpeL7Ruu","https://ap.wps.com/l/cbCaiafdZpeL7Ruu","pdf",182895,"English","# Introduction\n# Patients and Methods\n## Patients\n# Results\n# Conclusion","[{\"question\":\"What does BI-RADS category 3 indicate in breast ultrasound?\",\"answer\":\"BI-RADS category 3 implies a greater than 0% but ≤ 2% probability of malignancy, characteristic of a likely benign finding that warrants short-term follow-up.\"},{\"question\":\"How many ultrasound examinations were analyzed, and what proportion were BI-RADS 3?\",\"answer\":\"A total of 13,760 ultrasound examinations were performed, and BI-RADS category 3 findings accounted for 27% of all examinations (N=3,715).\"},{\"question\":\"What was the malignancy rate and average tumor size among BI-RADS 3 follow-ups?\",\"answer\":\"Among cases undergoing recommended short-term follow-up, malignancy was identified in 1.49% (N=5), with an average tumor size of 13.6 mm at detection.\"}]","Evaluation of BI-RADS 3 Ultrasound Findings - the Frequency and Incidence of Malignant Lesions, and Tumor Size | PDF",1790190314,15]